002675 东诚药业
已收盘 09-04 15:00:00
资讯
新帖
简况
股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》
证券之星 · 09-04 01:47
股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》
东诚药业（002675）披露回购公司股份进展情况公告，9月2日股价下跌1.22%
证券之星 · 09-02
东诚药业（002675）披露回购公司股份进展情况公告，9月2日股价下跌1.22%
股市必读：东诚药业新发布《关于全资子公司购买和转让下属公司股权的公告》
证券之星 · 08-26
股市必读：东诚药业新发布《关于全资子公司购买和转让下属公司股权的公告》
东诚药业最新公告：全资子公司购买和转让下属公司股权
证券之星 · 08-24
东诚药业最新公告：全资子公司购买和转让下属公司股权
东诚药业（002675）2026年中报简析：净利润同比增长5.74%，盈利能力上升
证券之星 · 08-23
东诚药业（002675）2026年中报简析：净利润同比增长5.74%，盈利能力上升
东诚药业(002675)6月30日股东户数2.99万户，较上期减少24.5%
证券之星 · 08-22
东诚药业(002675)6月30日股东户数2.99万户，较上期减少24.5%
图解东诚药业中报：第二季度单季净利润同比下降5.66%
证券之星 · 08-22
图解东诚药业中报：第二季度单季净利润同比下降5.66%
东诚药业（002675）披露实际控制人部分股权质押及解除质押公告，8月20日股价上涨0.37%
证券之星 · 08-20
东诚药业（002675）披露实际控制人部分股权质押及解除质押公告，8月20日股价上涨0.37%
股市必读：东诚药业新发布《关于实际控制人部分股权解除质押的公告》
证券之星 · 08-19
股市必读：东诚药业新发布《关于实际控制人部分股权解除质押的公告》
东诚药业（002675）披露实际控制人部分股权解除质押公告，8月17日股价下跌0.91%
证券之星 · 08-17
东诚药业（002675）披露实际控制人部分股权解除质押公告，8月17日股价下跌0.91%
东诚药业（002675）股东由守谊质押476.6万股，占总股本0.58%
证券之星 · 08-15
东诚药业（002675）股东由守谊质押476.6万股，占总股本0.58%
东诚药业最新公告：山西核药生产中心投入运营
证券之星 · 08-14
东诚药业最新公告：山西核药生产中心投入运营
东诚药业（002675）披露控股股东部分股权质押展期公告，8月12日股价下跌0.22%
证券之星 · 08-12
东诚药业（002675）披露控股股东部分股权质押展期公告，8月12日股价下跌0.22%
东诚药业(002675.SZ)：原料药贝米肝素钠上市申请获受理
智通财经 · 08-06
东诚药业(002675.SZ)：原料药贝米肝素钠上市申请获受理
股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》
证券之星 · 08-06
股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》
东诚药业（002675）披露回购公司股份进展情况公告，8月4日股价下跌0.46%
证券之星 · 08-04
东诚药业（002675）披露回购公司股份进展情况公告，8月4日股价下跌0.46%
股市必读：东诚药业新发布《关于公司原料药产品取得德国汉堡卫生当局颁发的GMP证书的公告》
证券之星 · 08-03
股市必读：东诚药业新发布《关于公司原料药产品取得德国汉堡卫生当局颁发的GMP证书的公告》
东诚药业最新公告：原料药产品获德国汉堡卫生当局GMP证书
证券之星 · 07-31
东诚药业最新公告：原料药产品获德国汉堡卫生当局GMP证书
东诚药业（002675）披露控股股东部分股权展期及补充质押公告，7月27日股价上涨2.26%
证券之星 · 07-27
东诚药业（002675）披露控股股东部分股权展期及补充质押公告，7月27日股价上涨2.26%
新股前瞻|核药产业爆发前夜，蓝纳成能否成为千亿赛道先行者？
智通财经 · 07-25
新股前瞻|核药产业爆发前夜，蓝纳成能否成为千亿赛道先行者？
暂无数据
公司概况
公司名称：
烟台东诚药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-05-25
主营业务：
烟台东诚药业集团股份有限公司的主营业务是核医药业务、化药业务。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。
发行价格：
26.00
{"stockData":{"symbol":"002675","market":"SZ","secType":"STK","nameCN":"东诚药业","latestPrice":12.74,"timestamp":1788505386000,"preClose":12.87,"halted":0,"volume":4828695,"delay":0,"changeRate":-0.0101,"floatShares":743000000,"shares":825000000,"eps":0.2435,"marketStatus":"已收盘","change":-0.13,"latestTime":"09-04 15:00:00","open":12.9,"high":12.95,"low":12.69,"amount":62004700,"amplitude":0.0202,"askPrice":12.75,"askSize":155,"bidPrice":12.74,"bidSize":535,"shortable":0,"etf":0,"ttmEps":0.2435,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":5,"adr":0,"adjPreClose":12.87,"symbolType":"stock","openAndCloseTimeList":[[1788485400000,1788492600000],[1788498000000,1788505200000]],"highLimit":14.16,"lowLimit":11.58,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":824595705,"isCdr":false,"pbRate":2.41,"roa":"--","peRate":52.320329,"roe":"2.16%","epsLYR":0.2372,"committee":0.713689,"marketValue":10505000000,"turnoverRate":0.0065,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-07。","floatMarketCap":9471000000},"requestUrl":"/m/hq/s/002675/tweets","defaultTab":"tweets","newsList":[{"id":"2664068658","title":"股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664068658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664068658?lang=zh_cn&edition=full","pubTime":"2026-09-04 01:47","pubTimestamp":1788457632,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，东诚药业报收于12.87元，下跌0.54%，换手率0.44%，成交量3.24万手，成交额4177.34万元。公司公告汇总：截至2026年8月31日，东诚药业已回购股份7,399,499股，占总股本0.90%，支付资金总额100,168,758.70元。公司公告汇总关于回购公司股份进展情况的公告烟台东诚药业集团股份有限公司于2025年12月31日召开董事会，审议通过以集中竞价方式回购股份的方案，拟使用自有及自筹资金回购股份，用于股权激励和/或员工持股计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810173","title":"东诚药业（002675）披露回购公司股份进展情况公告，9月2日股价下跌1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664810173?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:55","pubTimestamp":1788360912,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，东诚药业报收于12.94元，较前一交易日下跌1.22%，最新总市值为106.7亿元。该股当日开盘13.04元，最高13.1元，最低12.91元，成交额达6372.92万元，换手率为0.66%。近日，东诚药业发布《关于回购公司股份进展情况的公告》。公告显示，公司于2025年12月31日召开董事会，审议通过以集中竞价方式回购股份的方案，拟使用自有及自筹资金回购股份，用于股权激励和/或员工持股计划。回购进展符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200043342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662757517","title":"股市必读：东诚药业新发布《关于全资子公司购买和转让下属公司股权的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662757517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662757517?lang=zh_cn&edition=full","pubTime":"2026-08-26 05:28","pubTimestamp":1787693296,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，东诚药业报收于12.96元，上涨1.49%，换手率0.74%，成交量5.54万手，成交额7144.59万元。公司公告汇总关于全资子公司购买和转让下属公司股权的公告东诚药业全资子公司安迪科以4,020万元向广东回旋购买昆明回旋100%股权，以4,000万元购买四川回旋100%股权，并以121,454,650.80元向高尚医药出售广东回旋45%股份。本次交易不构成关联交易，亦不构成重大资产重组，已在公司总经理审批权限内，无需提交董事会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600008475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661278443","title":"东诚药业最新公告：全资子公司购买和转让下属公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2661278443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661278443?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:40","pubTimestamp":1787568035,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司全资子公司安迪科拟以4020万元向广东回旋购买昆明回旋100%股权，以4000万元购买四川回旋100%股权，同时以1.21亿元向高尚医药出售广东回旋45%股份。交易完成后，安迪科将持有昆明回旋和四川回旋100%股权，不再持有广东回旋股权。本次交易旨在整合核药生产中心布局，优化内部重叠产能，降低管理成本，提高运营效率。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400027061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661123272","title":"东诚药业（002675）2026年中报简析：净利润同比增长5.74%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2661123272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661123272?lang=zh_cn&edition=full","pubTime":"2026-08-23 06:12","pubTimestamp":1787436740,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期东诚药业发布2026年中报。截至本报告期末，公司营业总收入13.09亿元，同比下降5.41%，归母净利润9374.01万元，同比上升5.74%。按单季度数据看，第二季度营业总收入6.83亿元，同比下降2.04%，第二季度归母净利润6030.47万元，同比下降5.66%。本报告期东诚药业盈利能力上升，毛利率同比增幅13.96%，净利率同比增幅25.27%。本文数据来源于东诚药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300001873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661164222","title":"东诚药业(002675)6月30日股东户数2.99万户，较上期减少24.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661164222","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661164222?lang=zh_cn&edition=full","pubTime":"2026-08-22 17:08","pubTimestamp":1787389713,"startTime":"0","endTime":"0","summary":"证券之星消息，近日东诚药业披露，截至2026年6月30日公司股东户数为2.99万户，较3月31日减少9689.0户，减幅为24.5%。在化学制药行业个股中，东诚药业股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年3月31日至2026年6月30日，东诚药业区间跌幅为10.84%，在此期间股东户数减少9689.0户，减幅为24.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200014993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294463","title":"图解东诚药业中报：第二季度单季净利润同比下降5.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294463","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661294463?lang=zh_cn&edition=full","pubTime":"2026-08-22 01:30","pubTimestamp":1787333423,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业2026年中报显示，上半年度公司主营收入13.09亿元，同比下降5.41%；归母净利润9374.01万元，同比上升5.74%；扣非净利润8832.84万元，同比上升9.77%；其中2026年第二季度，公司单季度主营收入6.83亿元，同比下降2.04%；单季度归母净利润6030.47万元，同比下降5.66%；单季度扣非净利润5840.04万元，同比下降4.77%；负债率42.07%，投资收益412.39万元，财务费用8409.86万元，毛利率53.06%。财报数据概要请见下图:本文数据来源于东诚药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200001831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660323893","title":"东诚药业（002675）披露实际控制人部分股权质押及解除质押公告，8月20日股价上涨0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660323893","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660323893?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:27","pubTimestamp":1787236032,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘，东诚药业报收于13.39元，较前一交易日上涨0.37%，最新总市值为110.41亿元。近日，东诚药业披露《关于实际控制人部分股权质押及解除质押的公告》。截至2026年8月20日，由守谊持有公司股票103,305,678股，累计质押23,866,000股，占其所持股份的23.10%。本次新增质押19,100,000股，质押给招商证券股份有限公司，用于融资需求，质押期限自2026年8月18日至2027年8月18日。同时，解除质押17,830,000股，原质押起始日为2023年8月21日，解除日期为2026年8月19日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000045513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660918544","title":"股市必读：东诚药业新发布《关于实际控制人部分股权解除质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660918544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660918544?lang=zh_cn&edition=full","pubTime":"2026-08-19 02:18","pubTimestamp":1787077093,"startTime":"0","endTime":"0","summary":"公司公告汇总：实际控制人由守谊解除质押股份4,707,000股，解除后累计质押占其所持股份21.87%。公司公告汇总关于实际控制人部分股权解除质押的公告烟台东诚药业集团股份有限公司于2026年8月18日发布公告，公司实际控制人由守谊先生近期对其所持部分股份办理了解除质押手续。由守谊及其一致行动人资信状况良好，具备相应资金偿还能力，目前不存在平仓风险，不会导致公司实际控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660435663","title":"东诚药业（002675）披露实际控制人部分股权解除质押公告，8月17日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660435663","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660435663?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:29","pubTimestamp":1786976962,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，东诚药业报收于13.05元，较前一交易日下跌0.91%，最新总市值为107.61亿元。近日，烟台东诚药业集团股份有限公司发布公告称，公司实际控制人由守谊先生近期对其所持部分股份办理了解除质押手续。截至2026年8月17日，由守谊先生持有公司股份103,305,678股，累计质押22,596,000股，占其所持股份的21.87%。由守谊及其一致行动人资信状况良好，具备相应资金偿还能力，目前不存在平仓风险，不会导致公司实际控制权变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700035740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659123476","title":"东诚药业（002675）股东由守谊质押476.6万股，占总股本0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659123476","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659123476?lang=zh_cn&edition=full","pubTime":"2026-08-15 00:18","pubTimestamp":1786724302,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业8月15日公开信息显示，股东由守谊向国泰海通证券股份有限公司合计质押476.6万股，占总股本0.58%。质押详情见下表：截止本公告日，股东烟台东益生物工程有限公司已累计质押股份4141.0万股，占其持股总数的33.16%，股东由守谊已累计质押股份2730.3万股，占其持股总数的26.43%。东诚药业主营业务：主要业务分为原料药业务、制剂业务以及核医药业务三个板块。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081500000709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659811716","title":"东诚药业最新公告：山西核药生产中心投入运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2659811716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659811716?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:27","pubTimestamp":1786699651,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司全资子公司安迪科旗下山西安迪科药业收到山西省药监局下发的《放射性药品生产许可证》，新增山西晋中核药生产中心，药品为氟[18F]脱氧葡糖注射液。该中心已达投产要求，将助力开拓市场、提升销售收入，完善全国核药网络化布局。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400029068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658167905","title":"东诚药业（002675）披露控股股东部分股权质押展期公告，8月12日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658167905","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658167905?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:39","pubTimestamp":1786545555,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，东诚药业报收于13.31元，较前一交易日下跌0.22%，最新总市值为109.75亿元。该股当日开盘13.36元，最高13.51元，最低13.25元，成交额达1.27亿元，换手率为1.27%。近日，东诚药业披露《关于控股股东部分股权质押展期的公告》。公告显示，公司控股股东烟台东益生物工程有限公司将其持有的部分股权进行质押展期，合计质押22,000,000股，占其所持股份比例17.62%，占公司总股本比例2.67%。公司控股股东及其一致行动人资信状况良好，具备相应资金偿还能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657114631","title":"东诚药业(002675.SZ)：原料药贝米肝素钠上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657114631","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657114631?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:41","pubTimestamp":1786020083,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的关于原料药贝米肝素钠上市申请的《受理通知书》。贝米肝素钠为一种低分子量肝素，其制剂为贝米肝素钠注射液，适用于血液透析时预防体外循环中发生凝血、预防普外手术和骨科手术患者的血栓栓塞性疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657830524","title":"股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657830524","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657830524?lang=zh_cn&edition=full","pubTime":"2026-08-06 02:00","pubTimestamp":1785952850,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，东诚药业报收于12.84元，下跌0.39%，换手率0.72%，成交量5.38万手，成交额6895.65万元。当日关注点交易信息汇总：8月5日主力资金净流出236.91万元，占总成交额3.44%。公司公告汇总：截至7月31日，东诚药业已回购股份7,399,499股，占总股本0.90%，支付资金总额100,168,758.70元，回购用途为股权激励和/或员工持股计划。本次回购符合相关法律法规及公司既定方案。公司未在禁止期间回购股票，委托价格和交易时段均符合监管要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552045","title":"东诚药业（002675）披露回购公司股份进展情况公告，8月4日股价下跌0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656552045?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:46","pubTimestamp":1785854775,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，东诚药业报收于12.89元，较前一交易日下跌0.46%，最新总市值为106.29亿元。该股当日开盘12.99元，最高13.14元，最低12.86元，成交额达8419.96万元，换手率为0.87%。近日，东诚药业发布《关于回购公司股份进展情况的公告》。本次回购符合相关法律法规及公司既定方案。公司未在禁止期间回购股票，委托价格和交易时段均符合监管要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656343847","title":"股市必读：东诚药业新发布《关于公司原料药产品取得德国汉堡卫生当局颁发的GMP证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656343847","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656343847?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:20","pubTimestamp":1785694823,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，东诚药业报收于12.82元，上涨0.23%，换手率0.9%，成交量6.67万手，成交额8562.59万元。当日关注点交易信息汇总：7月31日主力资金净流出375.84万元，占总成交额4.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FDXSmain","FDXMmain","FDAXmain","002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655551364","title":"东诚药业最新公告：原料药产品获德国汉堡卫生当局GMP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2655551364","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655551364?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:40","pubTimestamp":1785505257,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司近日收到德国汉堡卫生当局颁发的肝素钠原料药、依诺肝素钠原料药、那屈肝素钙原料药和硫酸软骨素钠原料药GMP证书，有效期三年。此次认证标志着上述产品可继续在欧盟市场销售，为公司原料药海外市场拓展提供保障。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100040437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FDAXmain","002675","BK0239","FDXSmain","FDXMmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654504644","title":"东诚药业（002675）披露控股股东部分股权展期及补充质押公告，7月27日股价上涨2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654504644","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654504644?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:47","pubTimestamp":1785163632,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘，东诚药业报收于12.67元，较前一交易日上涨2.26%，最新总市值为104.48亿元。该股当日开盘12.4元，最高12.73元，最低12.35元，成交额达1.04亿元，换手率为1.11%。公告显示，公司控股股东烟台东益生物工程有限公司将其持有的部分公司股权进行展期及补充质押。截至公告日，东益生物累计质押41,410,000股，占其所持股份的33.16%。公司控股股东及其一致行动人资信状况良好，具备资金偿还能力，目前不存在平仓风险，不会导致实际控制权变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700035244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654205506","title":"新股前瞻|核药产业爆发前夜，蓝纳成能否成为千亿赛道先行者？","url":"https://stock-news.laohu8.com/highlight/detail?id=2654205506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654205506?lang=zh_cn&edition=full","pubTime":"2026-07-25 13:55","pubTimestamp":1784958933,"startTime":"0","endTime":"0","summary":"截至目前，公司多款核心产品已推进至临床后期，具备显著的先发优势。18F-LNC1005是另一款靶向FAP的候选诊断放射性药物，用于胃癌患者的PET影像。目前该药物已向NMPA提交III期前咨询会议申请，预期于2026年第四季度启动III期阶段，并于2027年完成。而本次东诚分拆上市的蓝纳成，目前仍处于研发投入期，亏损持续扩大。资产负债方面，截至2025年末公司流动资产2.64亿万元，流动负债6854.3万元，现金及等价物为2.57亿元。目前，蓝纳成已在山东烟台建成4886平方","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788700509516,"stockEarnings":[{"period":"1week","weight":-0.0124},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0151},{"period":"6month","weight":0.01},{"period":"1year","weight":-0.1985},{"period":"ytd","weight":-0.0672}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.0133},{"period":"3month","weight":-0.0242},{"period":"6month","weight":-0.0471},{"period":"1year","weight":0.0436},{"period":"ytd","weight":-0.0098}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台东诚药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"29858人(较上一季度减少24.50%)","perCapita":"24897股","listingDate":"2012-05-25","address":"山东省烟台市福山区烟台经济技术开发区长白山路7号","registeredCapital":"82459万元","survey":" 烟台东诚药业集团股份有限公司的主营业务是核医药业务、化药业务。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。","listedPrice":26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东诚药业,002675,东诚药业股票,东诚药业股票老虎,东诚药业股票老虎国际,东诚药业行情,东诚药业股票行情,东诚药业股价,东诚药业股市,东诚药业股票价格,东诚药业股票交易,东诚药业股票购买,东诚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}